New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
10:16 EDTTKMR, JOE, HMSY, TDC, XOMA, XPO, DKS, BCOR, DRTXHigh option volume stocks
High option volume stocks: TKMR JOE HMSY TDC XOMA XPO VGK DKS BCOR DRTX
News For TKMR;JOE;HMSY;TDC;XOMA;XPO;DKS;BCOR;DRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 17, 2014
09:46 EDTTKMRSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
October 16, 2014
07:23 EDTXOMAIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
October 15, 2014
15:34 EDTTKMRTekmira TKM-HBN preclinical study shows 'knockdown of HBV surface antigen'
Subscribe for More Information
10:49 EDTTKMREbola linked names rise again amid broader market sell-off
Subscribe for More Information
10:02 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:57 EDTTKMRLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:58 EDTTKMRTekmira volatility up, 2nd Texas health-care worker tests positive for Ebola
Subscribe for More Information
07:54 EDTDRTXDurata Therapeutics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
October 14, 2014
11:19 EDTTKMRNIH says several potential Ebola treatments under development
Subscribe for More Information
10:10 EDTTKMRNIH director says supporting BioCryst, Chimerix Ebola treatments
Subscribe for More Information
10:01 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:04 EDTTKMRChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
07:10 EDTDRTXDurata Therapeutics downgraded to Neutral from Outperform at Credit Suisse
Durata Therapeutics (DRTX ) is being acquired by Actavis (ACT) for $23 per share and $5 in contingent value rights and Credit Suisse does not believe a higher bid will emerge.
05:40 EDTTKMRTekmira partner Alnylam reports positive clinical data for Patisiran study
Tekmira Pharmaceuticals (TKMR) reported that Alnylam Pharmaceuticals (ALNY) presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension, or OLE, study in patients with Familial Amyloidotic Polyneuropathy, or FAP. Patisiran is an RNAi therapeutic targeting transthyretin, or TTR, in development for the treatment of TTR-mediated amyloidosis, or ATTR, which is enabled by Tekmira's lipid nanoparticle, or LNP, technology. Alnylam presented data at the American Neurological Association's 2014 Annual Meeting. Results showed a mean 0.95 point decrease in modified Neuropathy Impairment Score at six months in 19 patients with mNIS+7 data available for the current analysis. This decrease in neuropathy progression compares favorably with the 7 to 10 point increase in mNIS+7 at six months that can be estimated from historical data sets in untreated FAP patients with similar baseline characteristics.
October 13, 2014
07:12 EDTTKMROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
07:11 EDTTKMRTekmira volatility elevated, Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 12, 2014
19:26 EDTTKMRPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTTKMRCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTTKMRNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTTKMRTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use